Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/14031
Title: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab
oxaliplatin
and a fluoropyrimidine (RAISE): a randomised
double-blind
multicentre
phase 3 study
Authors: Tabernero J
Yoshino T
Cohn AL
Obermannova R
Bodoky G
Garcia-Carbonero R
Ciuleanu TE
Portnoy DC
Van Cutsem E
Grothey A
Garcia-Alfonso P
Yamazaki K
Clingan PR
Lonardi S
Kim TW
Simms L
Chang SC
Nasroulah F; RAISE Study Investigators.
Issue Date: 2015
Citation: Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.
metadata.dc.identifier.journaltitle: Lancet Oncol
URI: 
metadata.dc.identifier.doi: 10.1016/S1470-2045(15)70127-0
Appears in Collections:ISLHD research

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.